Potential of PARP inhibitors for metastatic breast cancer
Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA
Potential of PARP inhibitors for metastatic breast cancer ( Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA )
3 Jun 2019
PARP inhibitors are a promising alternative to chemotherapy for patients with me...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition t...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival ...
Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019
Ribociclib and endocrine therapy improves survival for pre-menopausal women with...
Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer ( Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
1 Jun 2019
Treating ovarian cancer patients with PARP inhibitors
Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA
Treating ovarian cancer patients with PARP inhibitors ( Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA )
8 May 2019
PARP inhibitors and their side effects in solid tumour therapy
Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA
PARP inhibitors and their side effects in solid tumour therapy ( Paula Anastasia - David Geffen School of Medicine at UCLA Los Angeles, USA )
8 May 2019
Benefits and challenges of using PARP inhibitors to treat metastatic breast canc...
Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA
Benefits and challenges of using PARP inhibitors to treat metastatic breast cancer ( Kimberly Halla - Arizona Oncology Associates PC, Scottsdale, USA )
8 May 2019
A clinical nurse specialist led multidisciplinary approach to breast cancer surv...
Colleen Zombek - Ohiohealth, Columbus, USA
A clinical nurse specialist led multidisciplinary approach to breast cancer survivorship ( Colleen Zombek - Ohiohealth, Columbus, USA )
8 May 2019
Providing safe care to hereditary cancer patients and families
Suzanne Mahon - Saint Louis University, Missouri, USA
Providing safe care to hereditary cancer patients and families ( Suzanne Mahon - Saint Louis University, Missouri, USA )
8 May 2019
Biomarkers of systemic inflammation linked to reduced clinical activity of atezo...
Luciana Molinero - Genentech, San Francisco, USA
Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC ( Luciana Molinero - Genentech, San Francisco, USA )
18 Apr 2019
KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after ...
Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea
KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy ( Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea )
15 Apr 2019